Latest news

Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CAIX-Targeted Radiopharmaceutical Program

Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study

CARB-X Funds The 3rd Round of Debiopharm’s Targeted Antibiotic Program To Combat Resistant N. Gonorrhoeae Infections

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant